Huiyang new life drug, a subsidiary of Kangenbei, has been approved for phase I clinical trial in the United States
-
Last Update: 2015-06-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Kangenbei (600572) announced in the evening of June 11 that Sichuan Huiyang life Engineering Co., Ltd., a joint-stock subsidiary of the company, obtained the phase I clinical trial license document from the US Food and Drug Administration (FDA) on June 6 for the study of the company's recombinant high-efficiency interferon complex (rsifn CO) used in the study of advanced solid tumors with known interferon anti-tumor activity In addition, Hong Kong kangenbai International Co., Ltd., a wholly-owned subsidiary of kangenbai, also received a circular letter from far east super laboratory Co., Ltd., a joint-stock company of kangenbai, concerning the acquisition of phase I clinical trial of recombinant high-efficiency interferon complex in the United States Founded in 1997, Sichuan Huiyang company is mainly engaged in the technical development of biological and medical engineering Its main research product is rsifn Co, which is still in the stage of new drug development Far east laboratory Co., Ltd was registered in the British Virgin Islands in October 2005 It is mainly engaged in the research and development of cancer treatment drugs based on recombinant high-efficiency interferon co products and technologies In July 2012, Kangenbei obtained 18.13% equity of Sichuan Huiyang company and far east laboratory company respectively Meanwhile, Yunnan Department Biotechnology Co., Ltd., a related unit of the company, owns 7.65% equity of Far East laboratory company.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
